Can Nanosonics FDA Clearance Drive Wider Adoption of Its CORIS System?
Source: Kapitales Research
Highlights:
Nanosonics Limited (ASX: NAN) gained nearly 3% with the CMP of AU$3.545, after announcing that its CORIS system received FDA 510(k) clearance for expanded endoscope indications.
The approval allows the system to support a broader range of endoscopes, potentially increasing its adoption in healthcare facilities focused on infection prevention.
The company has started a Controlled Market Release (CMR) in the United Kingdom, while preparing another regulatory submission to expand coverage further.
Nanosonics Limited (ASX: NAN) shares moved higher, gaining nearly 3% with the CMP of AU$3.545, after the healthcare technology company reported a significant regulatory milestone for its infection-prevention platform. The firm announced that the US FDA has issued a 510(k) clearance allowing broader endoscope indications for its CORIS system. The development marks an important step in the company’s plan to broaden the clinical applications of its technology and strengthen its presence in the global infection-control solutions market.
What does the FDA clearance mean?
The latest approval allows the CORIS system to process a wider range of endoscopes, expanding its functionality in medical environments where strict infection control is critical. The clearance builds on the earlier regulatory approval received for the system’s initial endoscope indication. By expanding compatibility with additional endoscope types, the company aims to increase the potential use of the technology in hospitals and healthcare facilities.
Where is the rollout beginning?
The company has already initiated a Controlled Market Release in the United Kingdom, which will allow it to gather real-world insights and operational feedback from early sites. Additional market-release locations are expected to be introduced in Australia and other regions, while plans for the United States rollout are expected to follow after the company gains experience from these early deployments.
What are the next steps?
Nanosonics is also progressing with plans to submit another FDA 510(k) application aimed at further expanding the system’s endoscope compatibility. Looking ahead, the company has outlined plans for a full commercial launch starting from FY27, with regional rollouts expected to occur gradually after the completion of the controlled market release programs. The regulatory progress could help support broader adoption of the company’s infection-prevention technology as healthcare providers continue to prioritise advanced sterilisation and patient safety standards.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Can Nanosonics FDA Clearance Drive Wider Adoption of Its CORIS System?
Highlights:
Nanosonics Limited (ASX: NAN) shares moved higher, gaining nearly 3% with the CMP of AU$3.545, after the healthcare technology company reported a significant regulatory milestone for its infection-prevention platform. The firm announced that the US FDA has issued a 510(k) clearance allowing broader endoscope indications for its CORIS system. The development marks an important step in the company’s plan to broaden the clinical applications of its technology and strengthen its presence in the global infection-control solutions market.
What does the FDA clearance mean?
The latest approval allows the CORIS system to process a wider range of endoscopes, expanding its functionality in medical environments where strict infection control is critical. The clearance builds on the earlier regulatory approval received for the system’s initial endoscope indication. By expanding compatibility with additional endoscope types, the company aims to increase the potential use of the technology in hospitals and healthcare facilities.
Where is the rollout beginning?
The company has already initiated a Controlled Market Release in the United Kingdom, which will allow it to gather real-world insights and operational feedback from early sites. Additional market-release locations are expected to be introduced in Australia and other regions, while plans for the United States rollout are expected to follow after the company gains experience from these early deployments.
What are the next steps?
Nanosonics is also progressing with plans to submit another FDA 510(k) application aimed at further expanding the system’s endoscope compatibility. Looking ahead, the company has outlined plans for a full commercial launch starting from FY27, with regional rollouts expected to occur gradually after the completion of the controlled market release programs. The regulatory progress could help support broader adoption of the company’s infection-prevention technology as healthcare providers continue to prioritise advanced sterilisation and patient safety standards.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au